The estimated Net Worth of Stephen M Bloch is at least $219 millió dollars as of 30 July 2018. Stephen Bloch owns over 727,273 units of Liquidia Corp stock worth over $26,017,525 and over the last 17 years he sold LQDA stock worth over $192,937,760. In addition, he makes $100,579 as Independent Chairman of the board at Liquidia Corp.
Sign up
Stephen Bloch LQDA stock SEC Form 4 insiders trading
Stephen has made over 50 trades of the Liquidia Corp stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 727,273 units of LQDA stock worth $8,000,003 on 30 July 2018.
The largest trade he's ever made was buying 727,273 units of Liquidia Corp stock on 30 July 2018 worth over $8,000,003. On average, Stephen trades about 27,850 units every 58 days since 2007. As of 30 July 2018 he still owns at least 2,563,303 units of Liquidia Corp stock.
You can see the complete history of Stephen Bloch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stephen Bloch biography
Dr. Stephen M. Bloch M.D. serves as Independent Chairman of the board of the Company. Dr. Bloch has been the Chairperson of our Board since October 2018 and has been a member of our Board since July 2009, a member of our Audit Committee since its formation in August 2016 and the Chairperson of our Compensation Committee since its formation in August 2016. Dr. Bloch is currently a director of a number of private life sciences companies and served as a director of Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) from September 2005 until April 2016. Dr. Bloch has been a general partner at Canaan Partners, a global venture capital firm, since November 2007. From August 2003 to November 2007, Dr. Bloch was a principal at Canaan Partners. From January 1995 to June 2002, Dr. Bloch was the founder and chief executive officer of Radiology Management Sciences, LLC, a specialty medical management company. Dr. Bloch graduated from Dartmouth College with a Bachelor of Arts. Dr. Bloch also holds a Doctor of Medicine from the University of Rochester and a Master of Arts in the History of Science and Public Policy from Harvard University. Bloch is qualified to serve on our Board due to his financial expertise, experience as a venture capitalist and his experience of serving on the board of directors for several public and private pharmaceutical and life sciences companies.
What is the salary of Stephen Bloch?
As the Independent Chairman of the board of Liquidia Corp, the total compensation of Stephen Bloch at Liquidia Corp is $100,579. There are 5 executives at Liquidia Corp getting paid more, with Neal Fowler having the highest compensation of $1,729,090.
How old is Stephen Bloch?
Stephen Bloch is 58, he's been the Independent Chairman of the board of Liquidia Corp since 2018. There are 6 older and 12 younger executives at Liquidia Corp. The oldest executive at Liquidia Corp is Ralph Snyderman, 80, who is the Independent Director.
What's Stephen Bloch's mailing address?
Stephen's mailing address filed with the SEC is 419 DAVIS DRIVE, SUITE 100, , MORRISVILLE, NC, 27560.
Insiders trading at Liquidia Corp
Over the last 6 years, insiders at Liquidia Corp have traded over $16,750,945 worth of Liquidia Corp stock and bought 12,456,625 units worth $100,694,400 . The most active insiders traders include Forest Baskett, Scott D Sandell és Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of $1,467,274. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth $23,792.
What does Liquidia Corp do?
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
What does Liquidia Corp's logo look like?
Complete history of Stephen Bloch stock trades at Amicus Therapeutics Inc, Marinus Pharmaceuticals Inc és Liquidia Corp
Liquidia Corp executives and stock owners
Liquidia Corp executives and other stock owners filed with the SEC include:
-
Neal Fowler,
Chief Executive Officer and Director -
Robert Lippe,
Chief Operations Officer -
Robert A. Lippe,
Chief Operations Officer -
Dr. Tushar Shah M.D.,
Sr. VP of Product Devel. & Chief Medical Officer -
Damian deGoa,
CEO & Director -
Stephen Bloch,
Independent Chairman of the board -
Ralph Snyderman,
Independent Director -
Raman Singh,
Independent Director -
Seth Rudnick,
Independent Director -
Arthur Kirsch,
Independent Director -
Katherine Rielly-Gauvin,
Independent Director -
Joanna Horobin,
Independent Director -
Dr. Roger A. Jeffs Ph.D.,
CEO & Director -
Tushar Shah,
Chief Medical Officer -
Jeri Thomas,
Senior Vice President - Commercial -
Robert Roscigno,
Senior Vice President - Product Development -
Benjamin Maynor,
Senior Vice President - Research & Development -
Steven Bariahtaris,
Interim Chief Financial Officer -
Celia Reyes-Hoke,
VP of People & Culture -
Scott Moomaw,
Sr. VP of Commercial -
Jason Adair,
Sr. VP of Corp. Devel. & Strategy -
Russell Schundler,
Gen. Counsel & Corp. Sec. -
Jennifer Almond,
Director of Investor Relations & Corp. Communications -
Michael Kaseta,
Chief Financial Officer -
Dr. Ginger Denison,
Co-Founder -
William R. Kenan Jr.,
Co-Founder -
Partners Lpjohnson David Ed...,
-
Ventures, Llceshelman Fredr...,
-
Damian De Goa,
Director -
Kevin K Gordon,
President and CFO -
Edward T Mathers,
Director -
Timothy Albury,
SVP, Chief Accounting Officer -
Lt Ltd Zahir Fares Xeraya,
-
Peter J Barris,
10% owner -
M James Barrett,
10% owner -
& Melinda Gates Foundation ...,
-
Group Iv, Llc Wakefield,
10% owner -
Group Iii, Llc Wakefield,
10% owner -
Venture Investments Ltd Mor...,
10% owner -
Product Development, Llc Wi...,
-
Viii Lp Canaan Partners Vii...,
-
Group Pte Ltdvorobyev Maxim...,
-
Capital Spc Ltdal Wealth Pa...,
-
Scott D Sandell,
10% owner -
Patrick J Kerins,
10% owner -
Forest Baskett,
10% owner -
East Ltd Bathurst Enterpris...,
-
Plc Gsk,
-
Enterprise Associates 12, L...,
-
Of North Carolina At Chapel...,
10% owner -
Capital Ii, Lp Sovereign's,
10% owner -
Revelation Healthcare Fund ...,
-
Family Credit Llc Series D ...,
-
Mutual Holdings, Inc. Medical,
10% owner -
Arthur Ma.M. Pappas Life Sc...,
-
Ltd Bathurst Enterprises Lt...,
-
David Edward Johnson,
Director -
Shawn Glidden,
VP,Legal Affairs and Secretary -
Richard D Katz,
Chief Financial Officer -
David Edward Caligan Partne...,
-
Michael Kaseta,
CFO and COO -
Florina Krawchick,
SVP, Human Resources -
Rajeev Saggar,
Chief Medical Officer -
Scott Moomaw,
Chief Commercial Officer -
Roger Jeffs,
Chief Executive Officer -
Russell Schundler,
General Counsel -
Paul B Manning,
Director -
Jason Adair,
Chief Business Officer